OWA
CSTL icon

Opal Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

Opal Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-339
Closed -$7.38K – 407
2024
Q2 		$7.38K Buy
+339
New +$7.55K ﹤0.01% 723

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Opal Wealth Advisors's CSTL Position: Q3 2024 in Review

Opal Wealth Advisors sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 339 shares — an estimated $7.38K sold.

Opal Wealth Advisors first reported a position in CSTL in Q2 2024 and held it in 1 quarter. The position peaked at $7.38K in Q2 2024. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Opal Wealth Advisors reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Opal Wealth Advisors sold 339 Castle Biosciences shares in Q3 2024, an estimated $7.38K.
  • Opal Wealth Advisors first reported a position in Castle Biosciences in Q2 2024 and held it in 1 quarter.
  • Opal Wealth Advisors's Castle Biosciences position peaked at $7.38K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Opal Wealth Advisors's 13F filing for Q3 2024, filed 15 Oct 2024.